Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML.
Batcha AMN, Buckup N, Bamopoulos SA, Jurinovic V, Rothenberg-Thurley M, Gittinger H, Ksienzyk B, Dufour A, Schneider S, Kontro M, Saad J, Heckmann CA, Sauerland C, Görlich D, Berdel WE, Wörmann BJ, Krug U, Braess J, Mansmann U, Hiddemann W, Spiekermann K, Metzeler KH, Herold T. Batcha AMN, et al. Among authors: sauerland c. Blood Adv. 2023 Mar 28;7(6):1040-1044. doi: 10.1182/bloodadvances.2022007988. Blood Adv. 2023. PMID: 36149944 Free PMC article.
A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.
Moser C, Jurinovic V, Sagebiel-Kohler S, Ksienzyk B, Batcha AMN, Dufour A, Schneider S, Rothenberg-Thurley M, Sauerland CM, Görlich D, Berdel WE, Krug U, Mansmann U, Hiddemann W, Braess J, Spiekermann K, Greif PA, Vosberg S, Metzeler KH, Kumbrink J, Herold T. Moser C, et al. Among authors: sauerland cm. Blood Adv. 2021 Nov 23;5(22):4752-4761. doi: 10.1182/bloodadvances.2021004814. Blood Adv. 2021. PMID: 34535016 Free PMC article.
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Middeke JM, Metzeler KH, Röllig C, Krämer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Görlich D, Sauerland C, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Wörmann B, Sockel K, von Bonin M, Herold T, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhäuser M, Stölzel F, Thiede C. Middeke JM, et al. Among authors: sauerland c. Blood Adv. 2022 Mar 8;6(5):1394-1405. doi: 10.1182/bloodadvances.2021004934. Blood Adv. 2022. PMID: 34794176 Free PMC article.
The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
Pastore F, Greif PA, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Braess J, Sauerland CM, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Spiekermann K. Pastore F, et al. PLoS One. 2014 Oct 9;9(10):e109759. doi: 10.1371/journal.pone.0109759. eCollection 2014. PLoS One. 2014. PMID: 25299584 Free PMC article. Clinical Trial.
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Scholl S, Hilgendorf I, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). Kunadt D, et al. Among authors: sauerland c. J Hematol Oncol. 2022 Sep 5;15(1):126. doi: 10.1186/s13045-022-01339-8. J Hematol Oncol. 2022. PMID: 36064577 Free PMC article.
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Lengfelder E, et al. Among authors: sauerland c. Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4. Eur J Haematol. 2018. PMID: 29114972 Clinical Trial.
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, Spiekermann K, Krug U, Braess J, Görlich D, Sauerland CM, Woermann B, Herold T, Berdel WE, Hiddemann W, Kroschinsky F, Schetelig J, Platzbecker U, Müller-Tidow C, Sauer T, Serve H, Baldus C, Schäfer-Eckart K, Kaufmann M, Krause S, Hänel M, Schliemann C, Hanoun M, Thiede C, Bornhäuser M, Wendt K, Middeke JM. Eckardt JN, et al. Among authors: sauerland cm. Haematologica. 2023 Mar 1;108(3):690-704. doi: 10.3324/haematol.2021.280027. Haematologica. 2023. PMID: 35708137 Free PMC article.
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG. Braess J, et al. Among authors: sauerland c. Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. Leukemia. 2018. PMID: 30275528 Free PMC article. Clinical Trial.
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W; German AML Cooperative Group (AMLCG). Fiegl M, et al. Among authors: sauerland c. Leukemia. 2014 May;28(5):1001-7. doi: 10.1038/leu.2013.297. Epub 2013 Oct 22. Leukemia. 2014. PMID: 24150216 Clinical Trial.
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Hiddemann W, Spiekermann K, Buske C, Feuring-Buske M, Braess J, Haferlach T, Schoch C, Kern W, Schnittger S, Berdel W, Wörmann B, Heinecke A, Sauerland C, Büchner T; German AML Cooperative Group. Hiddemann W, et al. Among authors: sauerland c. Crit Rev Oncol Hematol. 2005 Nov;56(2):235-45. doi: 10.1016/j.critrevonc.2005.07.004. Epub 2005 Oct 3. Crit Rev Oncol Hematol. 2005. PMID: 16207531 Review.
108 results